Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study

INTRODUCTION: Enzalutamide significantly improved clinical outcomes compared with placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) with disease progression despite androgen deprivation therapy (ADT) in the PREVAIL study. However, few patients from A...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Yeong-Shiau, Ahn, Hanjong, Han, Weiqing, Huang, Shu-Pin, Wu, Hsi-Chin, Ma, Lulin, Yamada, Shunsuke, Suga, Kazutaka, Xie, Li-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123068/
https://www.ncbi.nlm.nih.gov/pubmed/35397772
http://dx.doi.org/10.1007/s12325-022-02140-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123068/
https://www.ncbi.nlm.nih.gov/pubmed/35397772
http://dx.doi.org/10.1007/s12325-022-02140-2

Ejemplares similares